Health Trials

Acute Lymphoblastic Leukemia All Adult

2

Review clinical trials related to Acute Lymphoblastic Leukemia All Adult. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.

Participants needed: 19
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Updated: Dec 31, 2025Locations: 1
Eligibility criteria

Age 18 to 70 years old (inclusive of both age limits), no gender restrictions, n... [+7]

Patients deemed by the investigator to require long-term use of immunosuppressiv... [+8]

Read more
Status: Recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patients to proceed with allogeneic peripheral blood transplant (alloBMT). Those being asked to participate have high DSA levels that puts those being asked to participate at high risk of rejecting the available donor's blood stem cells and making those being asked to participate ineligible to receive a stem cell transplant.

Participants needed: 8
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUpdated: Sep 26, 2025Locations: 1
Eligibility criteria

Participates must meet all other institutional criteria for the planned reduced... [+6]

Previous exposure to Daratumumab-SC or other anti-CD38 therapy [+13]

Read more